ATE399555T1 - Behandlung der rheumatoiden arthritis mit imitanib - Google Patents

Behandlung der rheumatoiden arthritis mit imitanib

Info

Publication number
ATE399555T1
ATE399555T1 AT03704474T AT03704474T ATE399555T1 AT E399555 T1 ATE399555 T1 AT E399555T1 AT 03704474 T AT03704474 T AT 03704474T AT 03704474 T AT03704474 T AT 03704474T AT E399555 T1 ATE399555 T1 AT E399555T1
Authority
AT
Austria
Prior art keywords
treatment
rheumatoid arthritis
imitanib
formula
pharmaceutically acceptable
Prior art date
Application number
AT03704474T
Other languages
English (en)
Inventor
Heikki Joensuu
Original Assignee
Hyks Inst Ti Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyks Inst Ti Oy filed Critical Hyks Inst Ti Oy
Application granted granted Critical
Publication of ATE399555T1 publication Critical patent/ATE399555T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03704474T 2002-01-28 2003-01-27 Behandlung der rheumatoiden arthritis mit imitanib ATE399555T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds

Publications (1)

Publication Number Publication Date
ATE399555T1 true ATE399555T1 (de) 2008-07-15

Family

ID=9929858

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03704474T ATE399555T1 (de) 2002-01-28 2003-01-27 Behandlung der rheumatoiden arthritis mit imitanib

Country Status (23)

Country Link
US (2) US20060264443A1 (de)
EP (1) EP1471916B1 (de)
JP (1) JP4398731B2 (de)
KR (1) KR101030416B1 (de)
CN (1) CN1646130A (de)
AT (1) ATE399555T1 (de)
BR (1) BR0307286A (de)
CA (1) CA2473158C (de)
DE (1) DE60321888D1 (de)
DK (1) DK1471916T3 (de)
ES (1) ES2309299T3 (de)
GB (1) GB0201882D0 (de)
HK (1) HK1072192A1 (de)
IL (1) IL162983A (de)
MX (1) MXPA04007309A (de)
NO (1) NO328255B1 (de)
NZ (1) NZ534137A (de)
PL (1) PL212137B1 (de)
PT (1) PT1471916E (de)
RU (1) RU2322238C2 (de)
SI (1) SI1471916T1 (de)
WO (1) WO2003063844A2 (de)
ZA (1) ZA200405323B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003226209B2 (en) * 2002-03-21 2008-10-23 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
US20050130986A1 (en) * 2003-11-21 2005-06-16 Eklund Kari K. Treatment of spondylarthropathies
ATE546733T1 (de) * 2004-09-08 2012-03-15 Immunaid Pty Ltd Therapiestrategie zur behandlung von autoimmunkrankheiten und degenerativen erkrankungen
US20080032989A1 (en) * 2006-05-31 2008-02-07 Robinson William H Method of treating inflammatory diseases using tyroskine kinase inhibitors
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
RU2580656C1 (ru) * 2014-11-20 2016-04-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1414500A4 (de) * 2001-04-16 2005-01-12 Uab Research Foundation Akt und regulierung der synovialfibroblasten-apoptosis bei ra
US20040167134A1 (en) * 2001-05-16 2004-08-26 Christian Bruns Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1401415B1 (de) * 2001-06-29 2006-06-21 AB Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
CN1646130A (zh) 2005-07-27
DE60321888D1 (de) 2008-08-14
EP1471916B1 (de) 2008-07-02
PT1471916E (pt) 2008-10-03
IL162983A (en) 2010-06-16
KR20040086301A (ko) 2004-10-08
PL212137B1 (pl) 2012-08-31
ES2309299T3 (es) 2008-12-16
GB0201882D0 (en) 2002-03-13
PL370264A1 (en) 2005-05-16
NZ534137A (en) 2007-03-30
DK1471916T3 (da) 2008-10-20
NO20043585L (no) 2004-10-21
CA2473158A1 (en) 2003-08-07
HK1072192A1 (en) 2005-08-19
EP1471916A2 (de) 2004-11-03
MXPA04007309A (es) 2005-09-12
NO328255B1 (no) 2010-01-18
JP2005526022A (ja) 2005-09-02
US20060264443A1 (en) 2006-11-23
SI1471916T1 (sl) 2008-12-31
WO2003063844A2 (en) 2003-08-07
RU2322238C2 (ru) 2008-04-20
BR0307286A (pt) 2004-12-28
WO2003063844A3 (en) 2004-04-01
RU2004126447A (ru) 2005-07-10
US20090131382A1 (en) 2009-05-21
KR101030416B1 (ko) 2011-04-20
JP4398731B2 (ja) 2010-01-13
ZA200405323B (en) 2005-08-31
CA2473158C (en) 2013-06-11

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
HK1072192A1 (en) Treatment of rheumatoid arthritis using imatinib
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1471916

Country of ref document: EP